PT  - JOURNAL ARTICLE
AU  - Shishehbor, Mehdi H.
AU  - Hazen, Stanley L.
TI  - JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
AID  - 10.3949/ccjm.75a.08105
DP  - 2009 Jan 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 37--44
VI  - 76
IP  - 1
4099  - http://www.ccjm.org/content/76/1/37.short
4100  - http://www.ccjm.org/content/76/1/37.full
SO  - Cleve Clin J Med2009 Jan 01; 76
AB  - The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) (N Engl J Med 2008; 359:2195–2207) compared rosuvastatin (Crestor) 20 mg daily vs placebo in apparently healthy people who had levels of low-density lipoprotein cholesterol (LDL-C) lower than 130 mg/dL but elevated levels (≥ 2 mg/L) of high-sensitivity C-reactive protein (hs-CRP). Rosuvastatin treatment lowered LDL-C levels by 50% and hs-CRP levels by 37%, accompanied by a 44% relative risk reduction in the composite end point of unstable angina, revascularization, and confirmed death from cardiovascular causes. In absolute terms, 95 people had to be treated over 2 years to prevent one event. There was, however, a higher incidence of diabetes in the rosuvastatin group.